Pfizer treatment to stop smoking meets endpoints

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Pfizer (PFE -0.2%) says a clinical study measuring the efficacy and safety of its treatment to help smokers quit met its primary and secondary endpoints.

The study found patients treated with PFE's Chantix or Champix smoking cessation products (varenicline) were more likely to continue abstinence in the final weeks of the study than those without.

Chantix/Champix was approved by the FDA in 2006 for people 18 and older.